Power Law company profile

Syndax Pharmaceuticals

Biotech & Life Sciences · Waltham, United States · Founded 2005 · IPO 2016 Thoroughbred

Focused on developing an HDAC inhibitor for solid tumors and hematological tumors

Valuation

$1.82B

Market cap · May/2026

Revenue

$277M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

17 investors on Syndax Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

MPM BioImpact

Domain Associates

Series B+ 15 investors entered at this stage

Fidelity Investments

BioMed Ventures

Forward Ventures

Aisling Capital

OrbiMed

Delos Capital

Jennison Associates

Stanford University

EcoR1 Capital

Cormorant Asset Management

Foresite Capital

RMI Partners

SRI International

ArrowMark Partners

Avalon Ventures

Global footprint

Where Syndax Pharmaceuticals has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States99.6%

🇪🇸 Spain0.4%

🇦🇺 Australia0.4%

3 countries shown

Web traffic by country

17K monthly visits
across markets

🇺🇸 United States62.9%

🇨🇦 Canada11.2%

🇬🇧 United Kingdom9.4%

🇮🇳 India7.1%

🇫🇷 France4.7%

Top 5 markets shown

Market sentiment

What the market is saying about Syndax Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Syndax Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Syndax Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles